Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks
following initiation of therapy with the combination of Avastin and erlotinib in patients
with unresectable hepatocellular carcinoma (HCC). Progression-free survival is defined as the
time from initiation of therapy until documented disease progression or death.
Secondary objectives include: response rate, median and overall survival, toxicity and
tolerability, and to ascertain whether there is any correlation of response with prior
treatment status and underlying HCC risk factor(s).